Immuno-PET of the hepatocyte growth factor receptor met using the 1-armed antibody onartuzumab

Journal of Nuclear Medicine

Volumn 53, Issue 10, 2012, Pages 1592-1600

  Jagoda, Elaine M ^a   Lang, Lixin ^b   Bhadrasetty, Veerendra ^a   Histed, Stephanie ^a   Williams, Mark ^a   Kramer Marek, Gabriela ^a   Mena, Esther ^a   Rosenblum, Lauren ^a   Marik, Jan ^c   Tinianow, Jeff N ^c   Merchant, Mark ^c   Szajek, Lawrence ^d   Paik, Chang ^e   Cecchi, Fabiola ^a   Raffensperger, Kristen ^a   Jose Dizon, Joe Marie ^a   Bottaro, Donald P ^a   Choyke, Peter ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^c GENENTECH INC   (United States)

^d CLINICAL CENTER   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

76Bronartuzumab; 89Zr df onartuzumab; Immuno PET imaging; Met receptor; MetMAb

Indexed keywords

BROMINE ONARTUZUMAB BR 76; RADIOPHARMACEUTICAL AGENT; SCATTER FACTOR RECEPTOR; TRACER; UNCLASSIFIED DRUG; ZIRCONIUM DESFERRIOXAMINE ONARTUZUMAB ZR 89;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IMAGE QUALITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; BIOLOGICAL TRANSPORT; BROMINE RADIOISOTOPES; CELL LINE, TUMOR; FEMALE; HUMANS; ISOTOPE LABELING; MICE; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS C-MET; TUMOR BURDEN; ZIRCONIUM;

EID: 84867078746     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.102293     Document Type: Article

References (24)

1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4:915-925. (Pubitemid 37493640)
2. Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res. 2006;12:3657-3660. (Pubitemid 44000247)
3. Cappuzzo F, Janne PA, Skokan M, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol. 2009;20:298-304.
4. Martens T, Schmidt NO, Eckerich C, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res. 2006;12:6144-6152. (Pubitemid 44703780)
5. Jin H, Yang R, Zheng Z, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 2008;68:4360-4368.
6. Surati M, Patel P, Peterson A, Salgia R. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther. 2011;11:1655-1662.
7. Nayak TK, BrechbielMW. Radioimmunoimaging with longer-lived positron-emitting radionuclides: potentials and challenges. Bioconjug Chem. 2009;20:825-841.
8. 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med. 2003;44:1663-1670.
9. 89Zr-labelled monoclonal antibody DN30. Eur J Nucl Med Mol Imaging. 2008;35:1857-1867.
10. Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio PM. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci. 1998;111:237-247. (Pubitemid 28064148)
11. Athauda G, Giubellino A, Coleman JA, et al. c-Met ectodomain shedding rate correlates with malignant potential. Clin Cancer Res. 2006;12:4154-4162.
12. Bachleitner-Hofmann T, Sun MY, Chen CT, et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther. 2008;7:3499-3508.
13. Martin TA, Jiang WG. Hepatocyte growth factor and its receptor signalling complex as targets in cancer therapy. Anticancer Agents Med Chem. 2010;10:2-6.
14. Perk LR, Vosjan MJ, Visser GW, et al. p-Isothiocyanatobenzyl- desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging. Eur J Nucl Med Mol Imaging. 2010;37:250-259.
15. 89Zr-labeled monoclonal antibodies. J Nucl Med. 2003;44:1271-1281.
16. Szajek LP, Kao CHK, Kiesewetter DO, et al. Semi-remote production of Br-76 and preparation of high specific activity radiobrominated pharmaceuticals for PET studies. Radiochim Acta. 2004;92:291-295.
17. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72:77-89. (Pubitemid 14091996)
18. 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2 alpha receptorpositive tumor xenografts. Cancer Res. 1995;55:5323-5329.
19. Morris BJ. Specific radioactivity of radioimmunoassay tracer determined by self-displacement: a re-evaluation. Clin Chim Acta. 1976;73:213-216.
20. Guide for the Care and Use of Laboratory Animals. Bethesda, MD: National Institutes of Health; 1985. NIH publication 85-23.
21. Seidel J, Vaquero JJ, Green MV. Resolution uniformity and sensitivity of the NIH atlas small animal scanner: comparison to simulated LSO scanners without depth-of-interaction capability. IEEE Trans Nucl Sci. 2003;50:1347-1350.
22. 89Zr in mice. Nucl Med Biol. 2011;38:675-681.
23. Wu AM, Olafsen T. Antibodies for molecular imaging of cancer. Cancer J. 2008;14:191-197.
24. 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med. 2009;50:1828-1836.